Author Archives: Bruno Quinney

Modern medical science laboratory
#Cancer research #High throughput screening #Oncology #SPT Labtech

SPT Labtech & BellBrook Labs collaborate on oncology 

SPT Labtech and BellBrook Labs are collaborating to advance cancer research, having developed a miniaturised, high-throughput screening platform for the discovery and profiling of Vacuolar protein sorting associated protein 4B (VPS4B) ATPase inhibitors.   VPS4B has emerged as a high-priority therapeutic target in oncology due to its overexpression in specific tumours and its… Read More

#Cancer Research #News

#High throughput screening #SLAS2026

Carterra launches high-throughput SPR instrument  

High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the market leading system for small molecule through large molecule discovery and development workflows.  SPR platforms have… Read More

#News

Kidneys
#BioMed X #Diabetes #European Union #Kidney disease

Global research launched into early diabetic kidney disease 

Pharma innovation hub BioMed X has partnered with the government of Barbados to launch global research into a therapy for early diabetic kidney disease.  The new global call for research proposals, entitled ‘AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados’, addresses the biological heterogeneity of early diabetic kidney disease in… Read More

#Business & Investment #News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

#Oncology #Syncona #The Francis Crick Institute

ALTx Therapeutics launched to develop novel cancer treatments 

Slingshot Therapeutics has launched ALTx Therapeutics with funding worth £12.55 million ($17.04 million) to develop novel treatments for cancer.  ALTx Therapeutics launched into the Slingshot accelerator with backing from Syncona, the Francis Crick Institute and Cancer Research Horizons.  Spinning out of the Crick, ALTx is focused on developing therapeutics targeting vulnerabilities… Read More

#Business & Investment #Cancer Research #News

Lab automation
#AI #Automata #Automation / robotics #Danaher Corporation

Beckman Coulter partners with Automata on lab automation 

Danaher’s Beckman Coulter Life Sciences has partnered with robotics company Automata to accelerate AI-ready laboratory automation.  The strategic partnership will integrate Beckman Coulter Life Sciences’ liquid handling, genomic and cell analysis technologies with Automata’s AI-ready automation platform, enabling faster, more consistent and more scalable experimentation for research organisations.  The… Read More

#Business & Investment #News

The European Medicines Agency building
#CHMP #European Medicines Agency #Oncology

CHMP recommends combination therapy to treat anal cancer  

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer.  Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with… Read More

#Cancer Research #News

Cannabinoid research
#Assays #BMG Labtech #Cannabinoid #Drug discovery

The study of cannabinoid-based drugs: developments and opportunities

This paid-for advertorial by BMG Labtech appeared in DDW Volume 27 – Issue 1, Winter 2025/2026.   Scientists are exploring new strategies to advance drug discovery and development related to cannabinoid research due to significant unmet needs in different therapeutic areas. Microplate-based interaction assays show promise for the study of a wide range of cannabinoid signalling events. Developments in cannabinoid research… Read More

#Exclusive Content

Back pain
#Biotech #Chronic low back pain #FDA #Persica Pharmaceuticals

Therapeutic approach could treat chronic low back pain 

A targeted therapeutic approach could effectively treat chronic low back pain (cLBP), data suggests.  The Phase Ib trial of PP353, developed by biotechnology company Persica Pharmaceuticals, demonstrated a clinically meaningful and durable reduction in pain and disability in patients with chronic low back pain and Modic Type 1 changes. Results have… Read More

#News

Neurons in Parkinson's disease
#Nautilus Biotechnology #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation

$1.6m collaboration to advance Parkinson’s proteomics research 

A $1.6 million research effort is set to advance single-molecule proteomics research in Parkinson’s disease (PD).  Life sciences company Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar (WCM-Q) and The Michael J Fox Foundation (MJFF) to study the connection between the alpha-synuclein (aSyn) protein and PD.  … Read More

#Business & Investment #News

#Bacteria #Drug resistance #University of Sydney

Sugar-targeting antibody could kill drug-resistant bacteria

Sugar molecules found on bacterial cells could offer a target to killing drug-resistant bacteria, scientists suggest.  Researchers have designed antibodies that recognise the sugar found only on bacterial cells, which could underpin a new generation of immunotherapies for multidrug resistant hospital-acquired infections.  The findings, published in … Read More

#News

CT scans of the brain
#Alzheimer's #Biopharma #Clinical trial #Fast Track designation #FDA

Therapy could improve brain function in Alzheimer’s patients

An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.  Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease… Read More

#News

#AI #Biotech #Breast cancer #Clinical trial #Obesity

Why AI, obesity and breast cancer will dominate 2026

The latest episode of the DDW podcast is available to listen to below. This week, Bruno Quinney speaks to DDW Editor Reece Armstrong and Deputy Editor Diana Turner to look ahead to the world of drug discovery, pharma and biotech in 2026. They explore why AI will continue to dominate… Read More

#Featured Podcasts #Podcasts

#AI #Biomarkers #Machine learning #SLAS2026

The science behind SLAS2026 

DDW Editor Reece Armstrong examines some of the science that has emerged in the last year that is driving the conversations at SLAS 2026. SLAS always provides a great opportunity to assess what topics are in the minds of scientists within the drug discovery… Read More

#Exclusive Content

#AI #Drug discovery #United States

From the Editor: A year in turmoil

For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position… Read More

#Exclusive Content #Opinion